Bayh: Device tax a job-killing 'raid' on the industry; Illumina, Life take aim at Roche with Dx buys;

 @FierceMedDev: Boston Scientific won a CE mark for a Deep brain stimulation treatment of Parkinson's disease. More | Follow @FierceMedDev

 @MarkHFierce: Finally--the deal is done. Sony is officially investing $645M into Olympus and the two will partner on medical equipment. More | Follow @MarkHFierce

 @DamianFierce: The FDA is getting an earful from lawmakers over the hackability of medical devices. More | Follow @DamianFierce

> Former Democratic U.S. Sen. Evan Bayh of Indiana says the 2.3% device industry tax represents a "raid" on the industry and will threaten thousands of American jobs. Opinion (WSJ sub. req)

> With their recent diagnostics M&A activity, Illumina ($ILMN) and Life Technologies ($LIFE) are taking aim at diagnostics giant Roche ($RHHBY), Bloomberg says. Article

> Cook Medical unveiled a new distribution center in Baisweiler, Germany intended to serve as a delivery hub for its European business. Release

> Freedom Meditech obtained a $2 million line of credit to help ramp up manufacturing and distribution of its chronic disease detection device, pending regulatory approval. Story

> Ethicon is launching its next generation of powered endocutters for laparoscopic surgeries in the chest cavity. News

> Medical device company VBOX got FDA clearance for its Trooper wearable oxygen concentrator, designed to fit in a purse and allow patients greater freedom than other oxygen-providing devices. More

> Abbott Laboratories ($ABT) is just about ready to split in two, but the company hit a PR snag: Richard Gonzalez, the man tabbed to head pharma-focused AbbVie, may not have been entirely honest on his résumé. Report

Biotech News

 @FierceBiotech: The French government wants Sanofi 'guarantees' on the future of Toulouse R&D. More | Follow @FierceBiotech

 @JohnCFierce: Paratek - Ph3 antibiotic, lost a big Novartis deal last year - wants a $92M IPO? Hmmmm. More | Follow @JohnCFierce

 @RyanMFierce: A crisis of credentials? Abbott came clean that choice to lead pharma unit didn't finish college. More | Follow @RyanMFierce

> IPO priced for biotech working on drug against chin fat. Story

> UCB fails to set RA drug apart from Roche med in Phase II. More

> Novo Nordisk scuttles late-stage hemophilia drug over patient risk. Article

Pharma News

@FiercePharma: Japan OKs Novo Nordisk's long-acting insulin Tresiba, still awaiting decision from FDA. More | Follow @FiercePharma

> Roche should pick up AbbVie or BMS, analyst thinks. Story

> Regeneron keeps keeping on with Eylea. Article

> FDA tries to protect public from fake Internet pharmacies. News